Metabolic cooperation and competition in the tumor microenvironment: Implications for therapy

Frontiers in Oncology

Volumn 7, Issue APR, 2017, Pages

  Gupta, Seema ^a   Roy, Amrita ^b   Dwarakanath, Bilikere S ^c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b B S ABDUR RAHMAN CRESCENT INSTITUTE OF SCIENCE AND TECHNOLOGY   (India)

^c SRI RAMACHANDRA UNIVERSITY   (India)

Author keywords

Cancer cell metabolism; Cancer associated fibroblasts; Immune network; Metabolic cooperation; Metabolic reprogramming; Tumor microenvironment; Warburg effect

Indexed keywords

GLUTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 17; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN KINASE B;

ADIPOCYTE; AMINO ACID METABOLISM; ARTICLE; CANCER ASSOCIATED FIBROBLAST; CANCER CONTROL; CANCER SURVIVAL; CELL CYCLE CHECKPOINT; CELL DIFFERENTIATION; CELL FUNCTION; CELL METABOLISM; CELL PROLIFERATION; ENDOTHELIUM CELL; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HYPOXIA; IMMUNE RESPONSE; LIPID METABOLISM; MESENCHYME CELL; METABOLIC PARAMETERS; NUTRIENT AVAILABILITY; T LYMPHOCYTE; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR RESISTANCE;

EID: 85019037006     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2017.00068     Document Type: Article

References (338)

1. Warburg O. The Metabolism of Tumors. London: Constable and Co. (1930).
2. Martinez-Outschoorn U, Sotgia F, Lisanti MP. Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. Semin Oncol (2014) 41:195-216. doi:10.1053/j.seminoncol.2014.03.002
3. Choi SY, Collins CC, Gout PW, Wang Y. Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite? J Pathol (2013) 230:350-5. doi:10.1002/path.4218
4. Pearce EL, Pearce EJ. Metabolic pathways in immune cell activation and quiescence. Immunity (2013) 38:633-43. doi:10.1016/j.immuni.2013.04.005
5. Buck MD, O'Sullivan D, Pearce EL. T cell metabolism drives immunity. J Exp Med (2015) 212:1345-60. doi:10.1084/jem.20151159
6. O'Sullivan D, Pearce EL. Targeting T cell metabolism for therapy. Trends Immunol (2015) 36:71-80. doi:10.1016/j.it.2014.12.004
7. O'Sullivan D, van der Windt GJ, Huang SC, Curtis JD, Chang CH, Buck MD, et al. Memory CD8(+) T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development. Immunity (2014) 41:75-88. doi:10.1016/j.immuni.2014.06.005
8. Lunt SJ, Chaudary N, Hill RP. The tumor microenvironment and metastatic disease. Clin Exp Metastasis (2009) 26:19-34. doi:10.1007/s10585-008-9182-2
9. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer (2011) 11:85-95. doi:10.1038/nrc2981
10. Pavlides S, Vera I, Gandara R, Sneddon S, Pestell RG, Mercier I, et al. Warburg meets autophagy: cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis. Antioxid Redox Signal (2012) 16:1264-84. doi:10.1089/ars.2011.4243
11. Eckert AW, Wickenhauser C, Salins PC, Kappler M, Bukur J, Seliger B. Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma. J Transl Med (2016) 14:85. doi:10.1186/s12967-016-0828-6
12. Arora A, Singh S, Bhatt AN, Pandey S, Sandhir R, Dwarakanath BS. Interplay between metabolism and oncogenic process: role of microRNAs. Transl Oncogenomics (2015) 7:11-27. doi:10.4137/TOG.S29652
13. Kouidhi S, Noman MZ, Kieda C, Elgaaied AB, Chouaib S. Intrinsic and tumor microenvironment-induced metabolism adaptations of T cells and impact on their differentiation and function. Front Immunol (2016) 7:114. doi:10.3389/fimmu.2016.00114
14. Wu W, Zhao S. Metabolic changes in cancer: beyond the Warburg effect. Acta Biochim Biophys Sin (Shanghai) (2013) 45:18-26. doi:10.1093/abbs/gms104
15. Wang T, Liu G, Wang R. The intercellular metabolic interplay between tumor and immune cells. Front Immunol (2014) 5:358. doi:10.3389/fimmu.2014.00358
16. Siska PJ, Rathmell JC. T cell metabolic fitness in antitumor immunity. Trends Immunol (2015) 36:257-64. doi:10.1016/j.it.2015.02.007
17. Pisarsky L, Bill R, Fagiani E, Dimeloe S, Goosen RW, Hagmann J, et al. Targeting metabolic symbiosis to overcome resistance to anti-angiogenic therapy. Cell Rep (2016) 15:1161-74. doi:10.1016/j.celrep.2016.04.028
18. Nakajima EC, Van Houten B. Metabolic symbiosis in cancer: refocusing the Warburg lens. Mol Carcinog (2013) 52:329-37. doi:10.1002/mc.21863
19. Molon B, Cali B, Viola A. T cells and cancer: how metabolism shapes immunity. Front Immunol (2016) 7:20. doi:10.3389/fimmu.2016.00020
20. Mockler MB, Conroy MJ, Lysaght J. Targeting T cell immunometabolism for cancer immunotherapy; understanding the impact of the tumor microenvironment. Front Oncol (2014) 4:107. doi:10.3389/fonc.2014.00107
21. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer (2006) 6:392-401. doi:10.1038/nrc1877
22. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res (2010) 316:1324-31. doi:10.1016/j.yexcr.2010.02.045
23. Amatangelo MD, Bassi DE, Klein-Szanto AJ, Cukierman E. Stroma-derived three-dimensional matrices are necessary and sufficient to promote desmoplastic differentiation of normal fibroblasts. Am J Pathol (2005) 167:475-88. doi:10.1016/S0002-9440(10)62991-4
24. Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat Rev (2011) 37:63-74. doi:10.1016/j.ctrv.2010.05.001
25. Nagy JA, Chang SH, Dvorak AM, Dvorak HF. Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer (2009) 100:865-9. doi:10.1038/sj.bjc.6604929
26. Chiche J, Brahimi-Horn MC, Pouyssegur J. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cell Mol Med (2010) 14:771-94. doi:10.1111/j.1582-4934.2009.00994.x
27. Peppicelli S, Andreucci E, Ruzzolini J, Margheri F, Laurenzana A, Bianchini F, et al. Acidity of microenvironment as a further driver of tumor metabolic reprogramming. J Clin Cell Immunol (2017) 8:485-9. doi:10.4172/2155-9899.1000485
28. Justus CR, Sanderlin EJ, Yang LV. Molecular connections between cancer cell metabolism and the tumor microenvironment. Int J Mol Sci (2015) 16:11055-86. doi:10.3390/ijms160511055
29. Chen JL, Lucas JE, Schroeder T, Mori S, Wu J, Nevins J, et al. The genomic analysis of lactic acidosis and acidosis response in human cancers. PLoS Genet (2008) 4:e1000293. doi:10.1371/journal.pgen.1000293
30. Xie J, Wu H, Dai C, Pan Q, Ding Z, Hu D, et al. Beyond Warburg effect -dual metabolic nature of cancer cells. Sci Rep (2014) 4:4927. doi:10.1038/srep04927
31. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab (2008) 7:11-20. doi:10.1016/j.cmet.2007.10.002
32. Eigenbrodt E, Reinacher M, Scheefers-Borchel U, Scheefers H, Friis R. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit Rev Oncog (1992) 3:91-115.
33. Warburg O. On the origin of cancer cells. Science (1956) 123:309-14. doi:10.1126/science.123.3191.309
34. Bost F, Decoux-Poullot AG, Tanti JF, Clavel S. Energy disruptors: rising stars in anticancer therapy? Oncogenesis (2016) 5:e188. doi:10.1038/oncsis.2015.46
35. Slaninova V, Krafcikova M, Perez-Gomez R, Steffal P, Trantirek L, Bray SJ, et al. Notch stimulates growth by direct regulation of genes involved in the control of glycolysis and the tricarboxylic acid cycle. Open Biol (2016) 6:150155. doi:10.1098/rsob.150155
36. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol (2006) 16:253-64. doi:10.1016/j.semcancer.2006.07.014
37. Wilde BR, Ayer DE. Interactions between Myc and MondoA transcription factors in metabolism and tumourigenesis. Br J Cancer (2015) 113:1529-33. doi:10.1038/bjc.2015.360
38. Yeung SJ, Pan J, Lee MH. Roles of p53, MYC and HIF-1 in regulating glycolysis -the seventh hallmark of cancer. Cell Mol Life Sci (2008) 65:3981-99. doi:10.1007/s00018-008-8224-x
39. Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol (2006) 70:1469-80. doi:10.1124/mol.106.027029
40. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab (2006) 3:187-97. doi:10.1016/j.cmet.2006.01.012
41. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab (2006) 3:177-85. doi:10.1016/j.cmet.2006.02.002
42. Semenza GL. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol (2009) 19:12-6. doi:10.1016/j.semcancer.2008.11.009
43. Swietach P, Hulikova A, Vaughan-Jones RD, Harris AL. New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene (2010) 29:6509-21. doi:10.1038/onc.2010.455
44. Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, Wesley JB, et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem (2008) 283:10892-903. doi:10.1074/jbc.M800102200
45. Fukuda R, Zhang H, Kim JW, Shimoda L, Dang CV, Semenza GL. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell (2007) 129:111-22. doi:10.1016/j.cell.2007.01.047
46. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell (2007) 12:9-22. doi:10.1016/j.ccr.2007.05.008
47. Browne GJ, Proud CG. A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin. Mol Cell Biol (2004) 24:2986-97. doi:10.1128/MCB.24.7.2986-2997.2004
48. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res (1989) 49:6449-65.
49. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol (2004) 14:198-206. doi:10.1016/j.semradonc.2004.04.008
50. Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res (2002) 8:1284-91.
51. Williams AC, Collard TJ, Paraskeva C. An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: implications for clonal selection during colorectal carcinogenesis. Oncogene (1999) 18:3199-204. doi:10.1038/sj.onc.1202660
52. Putney LK, Barber DL. Na-H exchange-dependent increase in intracellular pH times G2/M entry and transition. J Biol Chem (2003) 278:44645-9. doi:10.1074/jbc.M308099200
53. Morita T. Low pH leads to sister-chromatid exchanges and chromosomal aberrations, and its clastogenicity is S-dependent. Mutat Res (1995) 334:301-8. doi:10.1016/0165-1161(95)90067-5
54. Morita T, Nagaki T, Fukuda I, Okumura K. Clastogenicity of low pH to various cultured mammalian cells. Mutat Res (1992) 268:297-305. doi:10.1016/0027-5107(92)90235-T
55. Snabaitis AK, Cuello F, Avkiran M. Protein kinase B/Akt phosphorylates and inhibits the cardiac Na+/H+ exchanger NHE1. Circ Res (2008) 103:881-90. doi:10.1161/CIRCRESAHA.108.175877
56. Meima ME, Webb BA, Witkowska HE, Barber DL. The sodium-hydrogen exchanger NHE1 is an Akt substrate necessary for actin filament reorganization by growth factors. J Biol Chem (2009) 284:26666-75. doi:10.1074/jbc.M109.019448
57. Jensen DH, Therkildsen MH, Dabelsteen E. A reverse Warburg metabolism in oral squamous cell carcinoma is not dependent upon myofibroblasts. J Oral Pathol Med (2015) 44:714-21. doi:10.1111/jop.12297
58. Starska K, Forma E, Jozwiak P, Brys M, Lewy-Trenda I, Brzezinska-Blaszczyk E, et al. Gene and protein expression of glucose transporter 1 and glucose transporter 3 in human laryngeal cancer-the relationship with regulatory hypoxia-inducible factor-1alpha expression, tumor invasiveness, and patient prognosis. Tumour Biol (2015) 36:2309-21. doi:10.1007/s13277-014-2838-4
59. Eckert AW, Lautner MH, Schutze A, Taubert H, Schubert J, Bilkenroth U. Coexpression of hypoxia-inducible factor-1alpha and glucose transporter-1 is associated with poor prognosis in oral squamous cell carcinoma patients. Histopathology (2011) 58:1136-47. doi:10.1111/j.1365-2559.2011.03806.x
60. Dwarakanath B, Jain V. Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy. Future Oncol (2009) 5:581-5. doi:10.2217/fon.09.44
61. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer (2002) 2:683-93. doi:10.1038/nrc882
62. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res (2006) 66:8927-30. doi:10.1158/0008-5472.CAN-06-1501
63. Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P, et al. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol (2007) 59:495-505. doi:10.1007/s00280-006-0291-9
64. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res (2005) 65:613-21.
65. Bhatt AN, Chauhan A, Khanna S, Rai Y, Singh S, Soni R, et al. Transient elevation of glycolysis confers radio-resistance by facilitating DNA repair in cells. BMC Cancer (2015) 15:335. doi:10.1186/s12885-015-1368-9
66. Kuo W, Lin J, Tang TK. Human glucose-6-phosphate dehydrogenase (G6PD) gene transforms NIH 3T3 cells and induces tumors in nude mice. Int J Cancer (2000) 85:857-64. doi:10.1002/(SICI)1097-0215(20000315)85:6>857::AID-IJC20<3.3.CO;2-L
67. Ramos-Montoya A, Lee WN, Bassilian S, Lim S, Trebukhina RV, Kazhyna MV, et al. Pentose phosphate cycle oxidative and nonoxidative balance: a new vulnerable target for overcoming drug resistance in cancer. Int J Cancer (2006) 119:2733-41. doi:10.1002/ijc.22227
68. Zanuy M, Ramos-Montoya A, Villacanas O, Canela N, Miranda A, Aguilar E, et al. Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle. Metabolomics (2012) 8:454-64. doi:10.1007/s11306-011-0328-x
69. Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis (2016) 5:e189. doi:10.1038/oncsis.2015.49
70. Santos CR, Schulze A. Lipid metabolism in cancer. FEBS J (2012) 279:2610-23. doi:10.1111/j.1742-4658.2012.08644.x
71. Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest (2013) 123:3678-84. doi:10.1172/JCI69600
72. Tajan M, Vousden KH. The Quid Pro Quo of the tumor/stromal interaction. Cell Metab (2016) 24:645-6. doi:10.1016/j.cmet.2016.10.017
73. Wang Q, Hardie RA, Hoy AJ, van Geldermalsen M, Gao D, Fazli L, et al. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. J Pathol (2015) 236:278-89. doi:10.1002/path.4518
74. van Geldermalsen M, Wang Q, Nagarajah R, Marshall AD, Thoeng A, Gao D, et al. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene (2016) 35:3201-8. doi:10.1038/onc.2015.381
75. Lamonte G, Tang X, Chen JL, Wu J, Ding CK, Keenan MM, et al. Acidosis induces reprogramming of cellular metabolism to mitigate oxidative stress. Cancer Metab (2013) 1:23. doi:10.1186/2049-3002-1-23
76. Perez-Escuredo J, Dadhich RK, Dhup S, Cacace A, Van Hee VF, De Saedeleer CJ, et al. Lactate promotes glutamine uptake and metabolism in oxidative cancer cells. Cell Cycle (2016) 15:72-83. doi:10.1080/15384101.2015.1120930
77. Ananieva E. Targeting amino acid metabolism in cancer growth and anti-tumor immune response. World J Biol Chem (2015) 6:281-9. doi:10.4331/wjbc.v6.i4.281
78. Pearce EL, Poffenberger MC, Chang CH, Jones RG. Fueling immunity: insights into metabolism and lymphocyte function. Science (2013) 342:1242454. doi:10.1126/science.1242454
79. Greiner EF, Guppy M, Brand K. Glucose is essential for proliferation and the glycolytic enzyme induction that provokes a transition to glycolytic energy production. J Biol Chem (1994) 269:31484-90.
80. Carr EL, Kelman A, Wu GS, Gopaul R, Senkevitch E, Aghvanyan A, et al. Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J Immunol (2010) 185:1037-44. doi:10.4049/jimmunol.0903586
81. Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci (2013) 1284:1-5. doi:10.1111/nyas.12105
82. Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell (2015) 162:1229-41. doi:10.1016/j.cell.2015.08.016
83. Crespo J, Sun H, Welling TH, Tian Z, Zou W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol (2013) 25:214-21. doi:10.1016/j.coi.2012.12.003
84. Guppy M, Greiner E, Brand K. The role of the Crabtree effect and an endogenous fuel in the energy metabolism of resting and proliferating thymocytes. Eur J Biochem (1993) 212:95-9. doi:10.1111/j.1432-1033.1993.tb17637.x
85. Marelli-Berg FM, Fu H, Mauro C. Molecular mechanisms of metabolic reprogramming in proliferating cells: implications for T-cell-mediated immunity. Immunology (2012) 136:363-9. doi:10.1111/j.1365-2567.2012.03583.x
86. Jacobs SR, Herman CE, Maciver NJ, Wofford JA, Wieman HL, Hammen JJ, et al. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J Immunol (2008) 180:4476-86. doi:10.4049/jimmunol.180.7.4476
87. Fox CJ, Hammerman PS, Thompson CB. Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol (2005) 5:844-52. doi:10.1038/nri1710
88. Bradley LM, Haynes L, Swain SL. IL-7: maintaining T-cell memory and achieving homeostasis. Trends Immunol (2005) 26:172-6. doi:10.1016/j.it.2005.01.004
89. Hammerman PS, Fox CJ, Thompson CB. Beginnings of a signal-transduction pathway for bioenergetic control of cell survival. Trends Biochem Sci (2004) 29:586-92. doi:10.1016/j.tibs.2004.09.008
90. Plas DR, Rathmell JC, Thompson CB. Homeostatic control of lymphocyte survival: potential origins and implications. Nat Immunol (2002) 3:515-21. doi:10.1038/ni0602-515
91. Nakaya M, Xiao Y, Zhou X, Chang JH, Chang M, Cheng X, et al. Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. Immunity (2014) 40:692-705. doi:10.1016/j.immuni.2014.04.007
92. Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC. Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem (2002) 277:21123-9. doi:10.1074/jbc.M110675200
93. Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood (2007) 109:1568-73. doi:10.1182/blood-2006-06-031856
94. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol (2013) 13:227-42. doi:10.1038/nri3405
95. Frauwirth KA, Thompson CB. Regulation of T lymphocyte metabolism. J Immunol (2004) 172:4661-5. doi:10.4049/jimmunol.172.8.4661
96. Dan HC, Ebbs A, Pasparakis M, Van Dyke T, Basseres DS, Baldwin AS. Akt-dependent activation of mTORC1 complex involves phosphorylation of mTOR (mammalian target of rapamycin) by IkappaB kinase alpha (IKKalpha). J Biol Chem (2014) 289:25227-40. doi:10.1074/jbc.M114.554881
97. Morita M, Gravel SP, Hulea L, Larsson O, Pollak M, St-Pierre J, et al. mTOR coordinates protein synthesis, mitochondrial activity and proliferation. Cell Cycle (2015) 14:473-80. doi:10.4161/15384101.2014.991572
98. Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity (2011) 35:871-82. doi:10.1016/j.immuni.2011.09.021
99. Peter C, Waldmann H, Cobbold SP. mTOR signalling and metabolic regulation of T cell differentiation. Curr Opin Immunol (2010) 22:655-61. doi:10.1016/j.coi.2010.08.010
100. Powell JD, Delgoffe GM. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity (2010) 33:301-11. doi:10.1016/j.immuni.2010.09.002
101. Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol (2011) 186:3299-303. doi:10.4049/jimmunol.1003613
102. Rubtsov YP, Niec RE, Josefowicz S, Li L, Darce J, Mathis D, et al. Stability of the regulatory T cell lineage in vivo. Science (2010) 329:1667-71. doi:10.1126/science.1191996
103. van der Windt GJ, Everts B, Chang CH, Curtis JD, Freitas TC, Amiel E, et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity (2012) 36:68-78. doi:10.1016/j.immuni.2011.12.007
104. Song JJ, Ott HC. Organ engineering based on decellularized matrix scaffolds. Trends Mol Med (2011) 17:424-32. doi:10.1016/j.molmed.2011.03.005
105. Darby IA, Laverdet B, Bonte F, Desmouliere A. Fibroblasts and myofibroblasts in wound healing. Clin Cosmet Investig Dermatol (2014) 7:301-11. doi:10.2147/CCID.S50046
106. Witz IP. The tumor microenvironment: the making of a paradigm. Cancer Microenviron (2009) 2(Suppl 1):9-17. doi:10.1007/s12307-009-0025-8
107. Bhome R, Bullock MD, Al Saihati HA, Goh RW, Primrose JN, Sayan AE, et al. A top-down view of the tumor microenvironment: structure, cells and signaling. Front Cell Dev Biol (2015) 3:33. doi:10.3389/fcell.2015.00033
108. Vannucci L. Stroma as an active player in the development of the tumor microenvironment. Cancer Microenviron (2015) 8:159-66. doi:10.1007/s12307-014-0150-x
109. Lee D, Ham IH, Son SY, Han SU, Kim YB, Hur H. Intratumor stromal proportion predicts aggressive phenotype of gastric signet ring cell carcinomas. Gastric Cancer (2016) 1-11. doi:10.1007/s10120-016-0669-2
110. Martinez-Outschoorn UE, Lisanti MP, Sotgia F. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin Cancer Biol (2014) 25:47-60. doi:10.1016/j.semcancer.2014.01.005
111. Fiaschi T, Marini A, Giannoni E, Taddei ML, Gandellini P, De Donatis A, et al. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res (2012) 72:5130-40. doi:10.1158/0008-5472.CAN-12-1949
112. Bonuccelli G, Avnet S, Grisendi G, Salerno M, Granchi D, Dominici M, et al. Role of mesenchymal stem cells in osteosarcoma and metabolic reprogramming of tumor cells. Oncotarget (2014) 5:7575-88. doi:10.18632/oncotarget.2243
113. Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, Ertel A, Flomenberg N, Witkiewicz AK, et al. Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle (2011) 10:1772-83. doi:10.4161/cc.10.11.15659
114. Shi H, Jiang H, Wang L, Cao Y, Liu P, Xu X, et al. Overexpression of monocarboxylate anion transporter 1 and 4 in T24-induced cancer-associated fibroblasts regulates the progression of bladder cancer cells in a 3D microfluidic device. Cell Cycle (2015) 14:3058-65. doi:10.1080/15384101.2015.1053666
115. Colegio OR. Lactic acid polarizes macrophages to a tumor-promoting state. Oncoimmunology (2016) 5:e1014774. doi:10.1080/2162402X.2015.1014774
116. Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature (2014) 513:559-63. doi:10.1038/nature13490
117. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity (2010) 32:593-604. doi:10.1016/j.immuni.2010.05.007
118. Liu M, Quek LE, Sultani G, Turner N. Epithelial-mesenchymal transition induction is associated with augmented glucose uptake and lactate production in pancreatic ductal adenocarcinoma. Cancer Metab (2016) 4:19. doi:10.1186/s40170-016-0160-x
119. Verdegem D, Moens S, Stapor P, Carmeliet P. Endothelial cell metabolism: parallels and divergences with cancer cell metabolism. Cancer Metab (2014) 2:19. doi:10.1186/2049-3002-2-19
120. Romero IL, Mukherjee A, Kenny HA, Litchfield LM, Lengyel E. Molecular pathways: trafficking of metabolic resources in the tumor microenvironment. Clin Cancer Res (2015) 21:680-6. doi:10.1158/1078-0432.CCR-14-2198
121. Berg JM, Tymoczko JL, Stryer L. Section 30.2, each organ has a unique metabolic profile. In: Freeman WH, editor. Biochemistry, 5th edn. New York: WH Freeman and Company (2002). Available from: https://www.ncbi.nlm.nih.gov/books/NBK22436/
122. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 21:309-22. doi:10.1016/j.ccr.2012.02.022
123. Ho PC, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R, et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell (2015) 162:1217-28. doi:10.1016/j.cell.2015.08.012
124. Li H, Zhang J, Chen SW, Liu LL, Li L, Gao F, et al. Cancer-associated fibroblasts provide a suitable microenvironment for tumor development and progression in oral tongue squamous cancer. J Transl Med (2015) 13:198. doi:10.1186/s12967-015-0551-8
125. Izar B, Joyce CE, Goff S, Cho NL, Shah PM, Sharma G, et al. Bidirectional cross talk between patient-derived melanoma and cancer-associated fibroblasts promotes invasion and proliferation. Pigment Cell Melanoma Res (2016) 29:656-68. doi:10.1111/pcmr.12513
126. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res (1999) 59:5002-11.
127. LaGory EL, Giaccia AJ. The ever-expanding role of HIF in tumour and stromal biology. Nat Cell Biol (2016) 18:356-65. doi:10.1038/ncb3330
128. Imtiyaz HZ, Simon MC. Hypoxia-inducible factors as essential regulators of inflammation. Curr Top Microbiol Immunol (2010) 345:105-20. doi:10.1007/82_2010_74
129. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer (2003) 3:721-32. doi:10.1038/nrc1187
130. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer (2008) 8:967-75. doi:10.1038/nrc2540
131. Clambey ET, McNamee EN, Westrich JA, Glover LE, Campbell EL, Jedlicka P, et al. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc Natl Acad Sci U S A (2012) 109:E2784-93. doi:10.1073/pnas.1202366109
132. Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 146:772-84. doi:10.1016/j.cell.2011.07.033
133. Ben-Shoshan J, Maysel-Auslender S, Mor A, Keren G, George J. Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur J Immunol (2008) 38:2412-8. doi:10.1002/eji.200838318
134. Shi LZ, Wang R, Huang G, Vogel P, Neale G, Green DR, et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med (2011) 208:1367-76. doi:10.1084/jem.20110278
135. Laoui D, Van Overmeire E, Di Conza G, Aldeni C, Keirsse J, Morias Y, et al. Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. Cancer Res (2014) 74:24-30. doi:10.1158/0008-5472.CAN-13-1196
136. Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg JI, et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature (2008) 456:814-8. doi:10.1038/nature07445
137. Wenes M, Shang M, Di Matteo M, Goveia J, Martin-Perez R, Serneels J, et al. Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis. Cell Metab (2016) 24:701-15. doi:10.1016/j.cmet.2016.09.008
138. Galvan-Pena S, O'Neill LA. Metabolic reprograming in macrophage polarization. Front Immunol (2014) 5:420. doi:10.3389/fimmu.2014.00420
139. Jetten N, Verbruggen S, Gijbels MJ, Post MJ, De Winther MP, Donners MM. Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo. Angiogenesis (2014) 17:109-18. doi:10.1007/s10456-013-9381-6
140. Jones CV, Williams TM, Walker KA, Dickinson H, Sakkal S, Rumballe BA, et al. M2 macrophage polarisation is associated with alveolar formation during postnatal lung development. Respir Res (2013) 14:41. doi:10.1186/1465-9921-14-41
141. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci (2012) 125:5591-6. doi:10.1242/jcs.116392
142. Kang CW, Dutta A, Chang LY, Mahalingam J, Lin YC, Chiang JM, et al. Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer. Sci Rep (2015) 5:15659. doi:10.1038/srep15659
143. Enninga EA, Nevala WK, Holtan SG, Leontovich AA, Markovic SN. Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanoma. Melanoma Res (2016) 26:429-41. doi:10.1097/CMR.0000000000000281
144. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med (2009) 15:1016-22. doi:10.1038/nm.2015
145. Sharp SP, Avram D, Stain SC, Lee EC. Local and systemic Th17 immune response associated with advanced stage colon cancer. J Surg Res (2017) 208:180-6. doi:10.1016/j.jss.2016.09.038
146. Han Y, Ye A, Bi L, Wu J, Yu K, Zhang S. Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia. Cancer Sci (2014) 105:933-42. doi:10.1111/cas.12459
147. Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, Mackman N, et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell (2003) 112:645-57. doi:10.1016/S0092-8674(03)00154-5
148. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, et al. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med (2010) 207:2439-53. doi:10.1084/jem.20100587
149. Schroeder T, Yuan H, Viglianti BL, Peltz C, Asopa S, Vujaskovic Z, et al. Spatial heterogeneity and oxygen dependence of glucose consumption in R3230Ac and fibrosarcomas of the Fischer 344 rat. Cancer Res (2005) 65:5163-71. doi:10.1158/0008-5472.CAN-04-3900
150. MacIver NJ, Michalek RD, Rathmell JC. Metabolic regulation of T lymphocytes. Annu Rev Immunol (2013) 31:259-83. doi:10.1146/annurev-immunol-032712-095956
151. Cham CM, Driessens G, O'Keefe JP, Gajewski TF. Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells. Eur J Immunol (2008) 38:2438-50. doi:10.1002/eji.200838289
152. Zheng Y, Delgoffe GM, Meyer CF, Chan W, Powell JD. Anergic T cells are metabolically anergic. J Immunol (2009) 183:6095-101. doi:10.4049/jimmunol.0803510
153. Chang CH, Curtis JD, Maggi LB Jr, Faubert B, Villarino AV, O'Sullivan D, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell (2013) 153:1239-51. doi:10.1016/j.cell.2013.05.016
154. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013
155. Plas DR, Thompson CB. Cell metabolism in the regulation of programmed cell death. Trends Endocrinol Metab (2002) 13:75-8. doi:10.1016/S1043-2760(01)00528-8
156. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer (2002) 2:647-56. doi:10.1038/nrc883
157. Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, et al. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity (2016) 45:374-88. doi:10.1016/j.immuni.2016.07.009
158. Yang M, Soga T, Pollard PJ. Oncometabolites: linking altered metabolism with cancer. J Clin Invest (2013) 123:3652-8. doi:10.1172/JCI67228
159. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood (2007) 109:3812-9. doi:10.1182/blood-2006-07-035972
160. Fukumura D, Xu L, Chen Y, Gohongi T, Seed B, Jain RK. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res (2001) 61:6020-4.
161. Calcinotto A, Filipazzi P, Grioni M, Iero M, De Milito A, Ricupito A, et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res (2012) 72:2746-56. doi:10.1158/0008-5472.CAN-11-1272
162. Ohashi T, Akazawa T, Aoki M, Kuze B, Mizuta K, Ito Y, et al. Dichloroacetate improves immune dysfunction caused by tumor-secreted lactic acid and increases antitumor immunoreactivity. Int J Cancer (2013) 133:1107-18. doi:10.1002/ijc.28114
163. Sattler UG, Meyer SS, Quennet V, Hoerner C, Knoerzer H, Fabian C, et al. Glycolytic metabolism and tumour response to fractionated irradiation. Radiother Oncol (2010) 94:102-9. doi:10.1016/j.radonc.2009.11.007
164. Martinez D, Vermeulen M, Trevani A, Ceballos A, Sabatte J, Gamberale R, et al. Extracellular acidosis induces neutrophil activation by a mechanism dependent on activation of phosphatidylinositol 3-kinase/Akt and ERK pathways. J Immunol (2006) 176:1163-71. doi:10.4049/jimmunol.176.2.1163
165. Fischer B, Muller B, Fischer KG, Baur N, Kreutz W. Acidic pH inhibits non-MHC-restricted killer cell functions. Clin Immunol (2000) 96:252-63. doi:10.1006/clim.2000.4904
166. Muller B, Fischer B, Kreutz W. An acidic microenvironment impairs the generation of non-major histocompatibility complex-restricted killer cells. Immunology (2000) 99:375-84. doi:10.1046/j.1365-2567.2000.00975.x
167. Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G, et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature (2013) 496:238-42. doi:10.1038/nature11986
168. Rubic T, Lametschwandtner G, Jost S, Hinteregger S, Kund J, Carballido-Perrig N, et al. Triggering the succinate receptor GPR91 on dendritic cells enhances immunity. Nat Immunol (2008) 9:1261-9. doi:10.1038/ni.1657
169. Villalba M, Rathore MG, Lopez-Royuela N, Krzywinska E, Garaude J, Allende-Vega N. From tumor cell metabolism to tumor immune escape. Int J Biochem Cell Biol (2013) 45:106-13. doi:10.1016/j.biocel.2012.04.024
170. Mocellin S, Bronte V, Nitti D. Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med Res Rev (2007) 27:317-52. doi:10.1002/med.20092
171. Cederbaum SD, Yu H, Grody WW, Kern RM, Yoo P, Iyer RK. Arginases I and II: do their functions overlap? Mol Genet Metab (2004) 81(Suppl 1):S38-44. doi:10.1016/j.ymgme.2003.10.012
172. Brito C, Naviliat M, Tiscornia AC, Vuillier F, Gualco G, Dighiero G, et al. Peroxynitrite inhibits T lymphocyte activation and proliferation by promoting impairment of tyrosine phosphorylation and peroxynitrite-driven apoptotic death. J Immunol (1999) 162:3356-66.
173. Aulak KS, Miyagi M, Yan L, West KA, Massillon D, Crabb JW, et al. Proteomic method identifies proteins nitrated in vivo during inflammatory challenge. Proc Natl Acad Sci U S A (2001) 98:12056-61. doi:10.1073/pnas.221269198
174. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med (2007) 13:828-35. doi:10.1038/nm1609
175. Kasic T, Colombo P, Soldani C, Wang CM, Miranda E, Roncalli M, et al. Modulation of human T-cell functions by reactive nitrogen species. Eur J Immunol (2011) 41:1843-9. doi:10.1002/eji.201040868
176. Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I, et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med (2005) 201:1257-68. doi:10.1084/jem.20042028
177. Predonzani A, Cali B, Agnellini AH, Molon B. Spotlights on immunological effects of reactive nitrogen species: when inflammation says nitric oxide. World J Exp Med (2015) 5:64-76. doi:10.5493/wjem.v5.i2.64
178. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res (2004) 64:5839-49. doi:10.1158/0008-5472.CAN-04-0465
179. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol (2005) 5:641-54. doi:10.1038/nri1668
180. Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS, et al. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer (2004) 100:826-33. doi:10.1002/cncr.20057
181. Phillips MM, Sheaff MT, Szlosarek PW. Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res Treat (2013) 45:251-62. doi:10.4143/crt.2013.45.4.251
182. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res (2010) 70:68-77. doi:10.1158/0008-5472.CAN-09-2587
183. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol (2013) 34:137-43. doi:10.1016/j.it.2012.10.001
184. Vacchelli E, Aranda F, Eggermont A, Sautes-Fridman C, Tartour E, Kennedy EP, et al. Trial watch: IDO inhibitors in cancer therapy. Oncoim-munology (2014) 3:e957994. doi:10.4161/21624011.2014.957994
185. Weinlich G, Murr C, Richardsen L, Winkler C, Fuchs D. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology (2007) 214:8-14. doi:10.1159/000096906
186. Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res (2011) 17:6985-91. doi:10.1158/1078-0432.CCR-11-1331
187. Gottfried E, Kreutz M, Mackensen A. Tumor metabolism as modulator of immune response and tumor progression. Semin Cancer Biol (2012) 22:335-41. doi:10.1016/j.semcancer.2012.02.009
188. Mellor AL, Chandler P, Baban B, Hansen AM, Marshall B, Pihkala J, et al. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int Immunol (2004) 16:1391-401. doi:10.1093/intimm/dxh140
189. Maciolek JA, Pasternak JA, Wilson HL. Metabolism of activated T lymphocytes. Curr Opin Immunol (2014) 27:60-74. doi:10.1016/j.coi.2014.01.006
190. Rabinowitz JD, White E. Autophagy and metabolism. Science (2010) 330:1344-8. doi:10.1126/science.1193497
191. Egan DF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W, et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science (2011) 331:456-61. doi:10.1126/science.1196371
192. Mason EF, Rathmell JC. Cell metabolism: an essential link between cell growth and apoptosis. Biochim Biophys Acta (2011) 1813:645-54. doi:10.1016/j.bbamcr.2010.08.011
193. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer (2009) 9:563-75. doi:10.1038/nrc2676
194. Son HJ, Lee J, Lee SY, Kim EK, Park MJ, Kim KW, et al. Metformin attenuates experimental autoimmune arthritis through reciprocal regulation of Th17/Treg balance and osteoclastogenesis. Mediators Inflamm (2014) 2014:973986. doi:10.1155/2014/973986
195. Murray IA, Patterson AD, Perdew GH. Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat Rev Cancer (2014) 14:801-14. doi:10.1038/nrc3846
196. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med (2003) 198:1875-86. doi:10.1084/jem.20030152
197. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 10:942-9. doi:10.1038/nm1093
198. Wilke CM, Wu K, Zhao E, Wang G, Zou W. Prognostic significance of regulatory T cells in tumor. Int J Cancer (2010) 127:748-58. doi:10.1002/ijc.25464
199. Gerriets VA, Kishton RJ, Johnson MO, Cohen S, Siska PJ, Nichols AG, et al. Foxp3 and toll-like receptor signaling balance Treg cell anabolic metabolism for suppression. Nat Immunol (2016) 17:1459-66. doi:10.1038/ni.3577
200. Macintyre AN, Gerriets VA, Nichols AG, Michalek RD, Rudolph MC, Deoliveira D, et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab (2014) 20:61-72. doi:10.1016/j.cmet.2014.05.004
201. Sinclair LV, Rolf J, Emslie E, Shi YB, Taylor PM, Cantrell DA. Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat Immunol (2013) 14:500-8. doi:10.1038/ni.2556
202. Wieman HL, Wofford JA, Rathmell JC. Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell (2007) 18:1437-46. doi:10.1091/mbc.E06-07-0593
203. McCracken AN, Edinger AL. Nutrient transporters: the Achilles' heel of anabolism. Trends Endocrinol Metab (2013) 24:200-8. doi:10.1016/j.tem.2013.01.002
204. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol (2005) 25:9543-53. doi:10.1128/MCB.25.21.9543-9553.2005
205. Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, et al. The CD28 signaling pathway regulates glucose metabolism. Immunity (2002) 16:769-77. doi:10.1016/S1074-7613(02)00323-0
206. Doering TA, Crawford A, Angelosanto JM, Paley MA, Ziegler CG, Wherry EJ. Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. Immunity (2012) 37:1130-44. doi:10.1016/j.immuni.2012.08.021
207. Shimatani K, Nakashima Y, Hattori M, Hamazaki Y, Minato N. PD-1+ memory phenotype CD4+ T cells expressing C/EBPalpha underlie T cell immunodepression in senescence and leukemia. Proc Natl Acad Sci U S A (2009) 106:15807-12. doi:10.1073/pnas.0908805106
208. Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA. PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2. Mol Cell Biol (2013) 33:3091-8. doi:10.1128/MCB.00319-13
209. Saha A, Aoyama K, Taylor PA, Koehn BH, Veenstra RG, Panoskaltsis-Mortari A, et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood (2013) 122:3062-73. doi:10.1182/blood-2013-05-500801
210. Walker LS, Sansom DM. Confusing signals: recent progress in CTLA-4 biology. Trends Immunol (2015) 36:63-70. doi:10.1016/j.it.2014.12.001
211. Chen X, Fosco D, Kline DE, Meng L, Nishi S, Savage PA, et al. PD-1 regulates extrathymic regulatory T-cell differentiation. Eur J Immunol (2014) 44:2603-16. doi:10.1002/eji.201344423
212. Ha TY. The role of regulatory T cells in cancer. Immune Netw (2009) 9:209-35. doi:10.4110/in.2009.9.6.209
213. Whiteside TL. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol (2012) 22:327-34. doi:10.1016/j.semcancer.2012.03.004
214. Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell LN, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun (2015) 6:6692. doi:10.1038/ncomms7692
215. Barsoum IB, Koti M, Siemens DR, Graham CH. Mechanisms of hypoxia-mediated immune escape in cancer. Cancer Res (2014) 74:7185-90. doi:10.1158/0008-5472.CAN-14-2598
216. Arreygue-Garcia NA, Daneri-Navarro A, del Toro-Arreola A, Cid-Arregui A, Gonzalez-Ramella O, Jave-Suarez LF, et al. Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer (2008) 8:16. doi:10.1186/1471-2407-8-16
217. Barsoum IB, Hamilton TK, Li X, Cotechini T, Miles EA, Siemens DR, et al. Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. Cancer Res (2011) 71:7433-41. doi:10.1158/0008-5472.CAN-11-2104
218. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 114:1537-44. doi:10.1182/blood-2008-12-195792
219. Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med (2014) 65:185-202. doi:10.1146/annurev-med-092012-112807
220. Chen TC, Wu CT, Wang CP, Hsu WL, Yang TL, Lou PJ, et al. Associations among pretreatment tumor necrosis and the expression of HIF-1alpha and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof. Oral Oncol (2015) 51:1004-10. doi:10.1016/j.oraloncology.2015.08.011
221. Barsoum IB, Smallwood CA, Siemens DR, Graham CH. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res (2014) 74:665-74. doi:10.1158/0008-5472.CAN-14-2598
222. Guido C, Whitaker-Menezes D, Capparelli C, Balliet R, Lin Z, Pestell RG, et al. Metabolic reprogramming of cancer-associated fibroblasts by TGF-beta drives tumor growth: connecting TGF-beta signaling with "Warburg-like" cancer metabolism and L-lactate production. Cell Cycle (2012) 11:3019-35. doi:10.4161/cc.21384
223. Guido C, Whitaker-Menezes D, Lin Z, Pestell RG, Howell A, Zimmers TA, et al. Mitochondrial fission induces glycolytic reprogramming in cancer-associated myofibroblasts, driving stromal lactate production, and early tumor growth. Oncotarget (2012) 3:798-810. doi:10.18632/oncotarget.574
224. Cai M, He J, Xiong J, Tay LW, Wang Z, Rog C, et al. Phospholipase D1-regulated autophagy supplies free fatty acids to counter nutrient stress in cancer cells. Cell Death Dis (2016) 7:e2448. doi:10.1038/cddis.2016.355
225. Schafer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol (2008) 9:628-38. doi:10.1038/nrm2455
226. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle (2009) 8:3984-4001. doi:10.4161/cc.8.23.10238
227. Martinez-Outschoorn UE, Balliet R, Lin Z, Whitaker-Menezes D, Birbe RC, Bombonati A, et al. BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies. Cell Cycle (2012) 11:4402-13. doi:10.4161/cc.22776
228. Xu XD, Shao SX, Cao YW, Yang XC, Shi HQ, Wang YL, et al. The study of energy metabolism in bladder cancer cells in co-culture conditions using a microfluidic chip. Int J Clin Exp Med (2015) 8:12327-36.
229. Yu T, Yang G, Hou Y, Tang X, Wu C, Wu XA, et al. Cytoplasmic GPER translocation in cancer-associated fibroblasts mediates cAMP/PKA/CREB/glycolytic axis to confer tumor cells with multidrug resistance. Oncogene (2016) 1-15. doi:10.1038/onc.2016.370
230. Arcucci A, Ruocco MR, Granato G, Sacco AM, Montagnani S. Cancer: an oxidative crosstalk between solid tumor cells and cancer associated fibroblasts. Biomed Res Int (2016) 2016:4502846. doi:10.1155/2016/4502846
231. Pertega-Gomes N, Vizcaino JR, Attig J, Jurmeister S, Lopes C, Baltazar F. A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer. BMC Cancer (2014) 14:352. doi:10.1186/1471-2407-14-352
232. Kim Y, Choi JW, Lee JH, Kim YS. Expression of lactate/H(+) symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and the Cancer Genome Atlas data analyses. Hum Pathol (2015) 46:104-12. doi:10.1016/j.humpath.2014.09.013
233. Miranda-Goncalves V, Granja S, Martinho O, Honavar M, Pojo M, Costa BM, et al. Hypoxia-mediated upregulation of MCT1 expression supports the glycolytic phenotype of glioblastomas. Oncotarget (2016) 7:46335-53. doi:10.18632/oncotarget.10114
234. Knudsen ES, Balaji U, Freinkman E, McCue P, Witkiewicz AK. Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential. Oncotarget (2016) 7(48):78396-411. doi:10.18632/oncotarget.11893
235. Burbridge MF, West DC, Atassi G, Tucker GC. The effect of extracellular pH on angiogenesis in vitro. Angiogenesis (1999) 3:281-8. doi:10.1023/A:1009092511894
236. Dong L, Li Z, Leffler NR, Asch AS, Chi JT, Yang LV. Acidosis activation of the proton-sensing GPR4 receptor stimulates vascular endothelial cell inflammatory responses revealed by transcriptome analysis. PLoS One (2013) 8:e61991. doi:10.1371/journal.pone.0061991
237. Zhang D, Wang Y, Shi Z, Liu J, Sun P, Hou X, et al. Metabolic reprogramming of cancer-associated fibroblasts by IDH3alpha downregulation. Cell Rep (2015) 10:1335-48. doi:10.1016/j.celrep.2015.02.006
238. Ko YH, Domingo-Vidal M, Roche M, Lin Z, Whitaker-Menezes D, Seifert E, et al. TP53-inducible glycolysis and apoptosis regulator (TIGAR) metabolically reprograms carcinoma and stromal cells in breast cancer. J Biol Chem (2016) 291:26291-303. doi:10.1074/jbc.M116.740209
239. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A (1997) 94:6658-63. doi:10.1073/pnas.94.13.6658
240. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, et al. p53 regulates mitochondrial respiration. Science (2006) 312:1650-3. doi:10.1126/science.1126863
241. Won KY, Lim SJ, Kim GY, Kim YW, Han SA, Song JY, et al. Regulatory role of p53 in cancer metabolism via SCO2 and TIGAR in human breast cancer. Hum Pathol (2012) 43:221-8. doi:10.1016/j.humpath.2011.04.021
242. Choi J, Stradmann-Bellinghausen B, Yakubov E, Savaskan NE, Regnier-Vigouroux A. Glioblastoma cells induce differential glutamatergic gene expressions in human tumor-associated microglia/macrophages and monocyte-derived macrophages. Cancer Biol Ther (2015) 16:1205-13. doi:10.1080/15384047.2015.1056406
243. Seo JW, Choi J, Lee SY, Sung S, Yoo HJ, Kang MJ, et al. Autophagy is required for PDAC glutamine metabolism. Sci Rep (2016) 6:37594. doi:10.1038/srep37594
244. Abramczyk H, Surmacki J, Kopec M, Olejnik AK, Lubecka-Pietruszewska K, Fabianowska-Majewska K. The role of lipid droplets and adipocytes in cancer. Raman imaging of cell cultures: MCF10A, MCF7, and MDA-MB-231 compared to adipocytes in cancerous human breast tissue. Analyst (2015) 140:2224-35. doi:10.1039/c4an01875c
245. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med (2011) 17:1498-503. doi:10.1038/nm.2492
246. Carter JC, Church FC. Mature breast adipocytes promote breast cancer cell motility. Exp Mol Pathol (2012) 92:312-7. doi:10.1016/j.yexmp.2012.03.005
247. D'Esposito V, Passaretti F, Hammarstedt A, Liguoro D, Terracciano D, Molea G, et al. Adipocyte-released insulin-like growth factor-1 is regulated by glucose and fatty acids and controls breast cancer cell growth in vitro. Diabetologia (2012) 55:2811-22. doi:10.1007/s00125-012-2629-7
248. Balaban S, Shearer RF, Lee LS, van Geldermalsen M, Schreuder M, Shtein HC, et al. Adipocyte lipolysis links obesity to breast cancer growth: adipocyte-derived fatty acids drive breast cancer cell proliferation and migration. Cancer Metab (2017) 5:1. doi:10.1186/s40170-016-0163-7
249. Wen YA, Xing X, Harris JW, Zaytseva YY, Mitov MI, Napier DL, et al. Adipocytes activate mitochondrial fatty acid oxidation and autophagy to promote tumor growth in colon cancer. Cell Death Dis (2017) 8:e2593. doi:10.1038/cddis.2017.21
250. Guaita-Esteruelas S, Guma J, Masana L, Borras J. The peritumoural adipose tissue microenvironment and cancer. The roles of fatty acid binding protein 4 and fatty acid binding protein 5. Mol Cell Endocrinol (2017). doi:10.1016/j.mce.2017.02.002
251. Gazi E, Gardner P, Lockyer NP, Hart CA, Brown MD, Clarke NW. Direct evidence of lipid translocation between adipocytes and prostate cancer cells with imaging FTIR microspectroscopy. J Lipid Res (2007) 48:1846-56. doi:10.1194/jlr.M700131-JLR200
252. Pascual G, Avgustinova A, Mejetta S, Martin M, Castellanos A, Attolini CS, et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature (2017) 541:41-5. doi:10.1038/nature20791
253. Li Z, Kang Y. Lipid metabolism fuels cancer's spread. Cell Metab (2017) 25:228-30. doi:10.1016/j.cmet.2017.01.016
254. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 324:1029-33. doi:10.1126/science.1160809
255. Liu Y, Zuckier LS, Ghesani NV. Dominant uptake of fatty acid over glucose by prostate cells: a potential new diagnostic and therapeutic approach. Anticancer Res (2010) 30:369-74.
256. Deep G, Schlaepfer IR. Aberrant lipid metabolism promotes prostate cancer: role in cell survival under hypoxia and extracellular vesicles biogenesis. Int J Mol Sci (2016) 17:1061-74. doi:10.3390/ijms17071061
257. Staron MM, Gray SM, Marshall HD, Parish IA, Chen JH, Perry CJ, et al. The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. Immunity (2014) 41:802-14. doi:10.1016/j.immuni.2014.10.013
258. Farooque A, Singh N, Adhikari JS, Afrin F, Dwarakanath BS. Enhanced antitumor immunity contributes to the radio-sensitization of Ehrlich ascites tumor by the glycolytic inhibitor 2-deoxy-D-glucose in mice. PLoS One (2014) 9:e108131. doi:10.1371/journal.pone.0108131
259. Farooque A, Afrin F, Adhikari JS, Dwarakanath BS. Polarization of macrophages towards M1 phenotype by a combination of 2-deoxy-d-glucose and radiation: implications for tumor therapy. Immunobiology (2016) 221:269-81. doi:10.1016/j.imbio.2015.10.009
260. Hubert S, Rissiek B, Klages K, Huehn J, Sparwasser T, Haag F, et al. Extracellular NAD+ shapes the Foxp3+ regulatory T cell compartment through the ART2-P2X7 pathway. J Exp Med (2010) 207:2561-8. doi:10.1084/jem.20091154
261. Leone RD, Lo YC, Powell JD. A2aR antagonists: next generation checkpoint blockade for cancer immunotherapy. Comput Struct Biotechnol J (2015) 13:265-72. doi:10.1016/j.csbj.2015.03.008
262. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest (2008) 118:3930-42. doi:10.1172/JCI36843
263. Blagosklonny MV. Flavopiridol, an inhibitor of transcription: implications, problems and solutions. Cell Cycle (2004) 3:1537-42. doi:10.4161/cc.3.12.1278
264. Lee K, Zhang H, Qian DZ, Rey S, Liu JO, Semenza GL. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci U S A (2009) 106:17910-5. doi:10.1073/pnas.0909353106
265. Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A (2008) 105:19579-86. doi:10.1073/pnas.0809763105
266. Yang QC, Zeng BF, Shi ZM, Dong Y, Jiang ZM, Huang J, et al. Inhibition of hypoxia-induced angiogenesis by trichostatin A via suppression of HIF-1a activity in human osteosarcoma. J Exp Clin Cancer Res (2006) 25:593-9.
267. Doedens AL, Phan AT, Stradner MH, Fujimoto JK, Nguyen JV, Yang E, et al. Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen. Nat Immunol (2013) 14:1173-82. doi:10.1038/ni.2714
268. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov (2011) 10:417-27. doi:10.1038/nrd3455
269. Maione F, Capano S, Regano D, Zentilin L, Giacca M, Casanovas O, et al. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J Clin Invest (2012) 122:1832-48. doi:10.1172/JCI58976
270. Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest (2013) 123:4479-88. doi:10.1172/JCI69589
271. Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature (2009) 460:103-7. doi:10.1038/nature08097
272. Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res (2011) 71:4366-72. doi:10.1158/0008-5472.CAN-10-1769
273. Blandino G, Valerio M, Cioce M, Mori F, Casadei L, Pulito C, et al. Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nat Commun (2012) 3:865. doi:10.1038/ncomms1859
274. Waickman AT, Powell JD. mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol Rev (2012) 249:43-58. doi:10.1111/j.1600-065X.2012.01152.x
275. Rao RR, Li Q, Odunsi K, Shrikant PA. The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity (2010) 32:67-78. doi:10.1016/j.immuni.2009.10.010
276. Li C, Capan E, Zhao Y, Zhao J, Stolz D, Watkins SC, et al. Autophagy is induced in CD4+ T cells and important for the growth factor-withdrawal cell death. J Immunol (2006) 177:5163-8. doi:10.4049/jimmunol.177.8.5163
277. Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol (2005) 56:47-60. doi:10.1016/j.critrevonc.2004.09.009
278. Sharma MD, Shinde R, McGaha TL, Huang L, Holmgaard RB, Wolchok JD, et al. The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment. Sci Adv (2015) 1:e1500845. doi:10.1126/sciadv.1500845
279. Yang S, de Souza P, Alemao E, Purvis J. Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha. Br J Cancer (2010) 102:1456-60. doi:10.1038/sj.bjc.6605647
280. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 372:449-56. doi:10.1016/S0140-6736(08)61039-9
281. Martelli AM, Chiarini F, Evangelisti C, Cappellini A, Buontempo F, Bressanin D, et al. Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget (2012) 3:371-94. doi:10.18632/oncotarget.477
282. Wang H, Wang L, Zhang Y, Wang J, Deng Y, Lin D. Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth. Cancer Cell Int (2016) 16:9. doi:10.1186/s12935-016-0280-y
283. Botzer LE, Maman S, Sagi-Assif O, Meshel T, Nevo I, Yron I, et al. Hexokinase 2 is a determinant of neuroblastoma metastasis. Br J Cancer (2016) 114:759-66. doi:10.1038/bjc.2016.26
284. Brown J. Effects of 2-deoxyglucose on carbohydrate metablism: review of the literature and studies in the rat. Metabolism (1962) 11:1098-112.
285. McComb RB, Yushok WD. Metabolism of ascites tumor cells. Iv. Enzymatic reactions involved in adenosinetriphosphate degradation induced by 2-deoxyglucose. Cancer Res (1964) 24:198-205.
286. Dwarakanath BS. Cytotoxicity, radiosensitization, and chemosensitization of tumor cells by 2-deoxy-D-glucose in vitro. J Cancer Res Ther (2009) 5(Suppl 1):S27-31. doi:10.4103/0973-1482.55137
287. Mohanti BK, Rath GK, Anantha N, Kannan V, Das BS, Chandramouli BA, et al. Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys (1996) 35:103-11. doi:10.1016/S0360-3016(96)85017-6
288. Singh D, Banerji AK, Dwarakanath BS, Tripathi RP, Gupta JP, Mathew TL, et al. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol (2005) 181:507-14. doi:10.1007/s00066-005-1320-z
289. Dwarakanath BS, Singh D, Banerji AK, Sarin R, Venkataramana NK, Jalali R, et al. Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects. J Cancer Res Ther (2009) 5(Suppl 1):S21-6. doi:10.4103/0973-1482.55136
290. Venkataramanaa NK, Venkatesh PK, Dwarakanath BS, Vani S. Protective effect on normal brain tissue during a combinational therapy of 2-deoxy-d-glucose and hypofractionated irradiation in malignant gliomas. Asian J Neurosurg (2013) 8:9-14. doi:10.4103/1793-5482.110274
291. Marko AJ, Miller RA, Kelman A, Frauwirth KA. Induction of glucose metabolism in stimulated T lymphocytes is regulated by mitogen-activated protein kinase signaling. PLoS One (2010) 5:e15425. doi:10.1371/journal.pone.0015425
292. Strum SB, Adalsteinsson O, Black RR, Segal D, Peress NL, Waldenfels J. Case report: sodium dichloroacetate (DCA) inhibition of the "Warburg Effect" in a human cancer patient: complete response in non-Hodgkin's lymphoma after disease progression with rituximab-CHOP. J Bioenerg Biomembr (2013) 45:307-15. doi:10.1007/s10863-013-9516-x
293. Jiang P, Du W, Wu M. Regulation of the pentose phosphate pathway in cancer. Protein Cell (2014) 5:592-602. doi:10.1007/s13238-014-0082-8
294. Tsouko E, Khan AS, White MA, Han JJ, Shi Y, Merchant FA, et al. Regulation of the pentose phosphate pathway by an androgen receptor-mTOR-mediated mechanism and its role in prostate cancer cell growth. Oncogenesis (2014) 3:e103. doi:10.1038/oncsis.2014.18
295. Sharma PK, Dwarakanath BS, Varshney R. Radiosensitization by 2-deoxy-D-glucose and 6-aminonicotinamide involves activation of redox sensitive ASK1-JNK/p38MAPK signaling in head and neck cancer cells. Free Radic Biol Med (2012) 53:1500-13. doi:10.1016/j.freeradbiomed.2012.07.001
296. Varshney R, Dwarakanath B, Jain V. Radiosensitization by 6-aminonicotinamide and 2-deoxy-D-glucose in human cancer cells. Int J Radiat Biol (2005) 81:397-408. doi:10.1080/09553000500148590
297. Varshney R, Gupta S, Dwarakanath BS. Radiosensitization of murine Ehrlich ascites tumor by a combination of 2-deoxy-D-glucose and 6-aminonicotinamide. Technol Cancer Res Treat (2004) 3:659-63. doi:10.1177/153303460400300616
298. Zhu W, Ye L, Zhang J, Yu P, Wang H, Ye Z, et al. PFK15, a small molecule inhibitor of PFKFB3, induces cell cycle arrest, apoptosis and inhibits invasion in gastric cancer. PLoS One (2016) 11:e0163768. doi:10.1371/journal.pone.0163768
299. Li S, Wu L, Feng J, Li J, Liu T, Zhang R, et al. In vitro and in vivo study of epigallocatechin-3-gallate-induced apoptosis in aerobic glycolytic hepatocellular carcinoma cells involving inhibition of phosphofructokinase activity. Sci Rep (2016) 6:28479. doi:10.1038/srep28479
300. Lian N, Jin H, Zhang F, Wu L, Shao J, Lu Y, et al. Curcumin inhibits aerobic glycolysis in hepatic stellate cells associated with activation of adenosine monophosphate-activated protein kinase. IUBMB Life (2016) 68:589-96. doi:10.1002/iub.1518
301. Cantelmo AR, Conradi LC, Brajic A, Goveia J, Kalucka J, Pircher A, et al. Inhibition of the glycolytic activator PFKFB3 in endothelium induces tumor vessel normalization, impairs metastasis, and improves chemotherapy. Cancer Cell (2016) 30:968-85. doi:10.1016/j.ccell.2016.10.006
302. Majkowska-Skrobek G, Augustyniak D, Lis P, Bartkowiak A, Gonchar M, Ko YH, et al. Killing multiple myeloma cells with the small molecule 3-bromopyruvate: implications for therapy. Anticancer Drugs (2014) 25:673-82. doi:10.1097/CAD.0000000000000094
303. Lis P, Dylag M, Niedzwiecka K, Ko YH, Pedersen PL, Goffeau A, et al. The HK2 dependent "Warburg effect" and mitochondrial oxidative phosphorylation in cancer: targets for effective therapy with 3-bromopyruvate. Molecules (2016) 21:E1730. doi:10.3390/molecules21121730
304. Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest (2013) 123:3685-92. doi:10.1172/JCI69741
305. Papaldo P, Lopez M, Cortesi E, Cammilluzzi E, Antimi M, Terzoli E, et al. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. J Clin Oncol (2003) 21:3462-8. doi:10.1200/JCO.2003.03.034
306. Di Cosimo S, Ferretti G, Papaldo P, Carlini P, Fabi A, Cognetti F. Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors. Drugs Today (Barc) (2003) 39:157-74. doi:10.1358/dot.2003.39.3.799451
307. Fang J, Quinones QJ, Holman TL, Morowitz MJ, Wang Q, Zhao H, et al. The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol Pharmacol (2006) 70:2108-15. doi:10.1124/mol.106.026245
308. Yu H, Zhang H, Dong M, Wu Z, Shen Z, Xie Y, et al. Metabolic reprogramming and AMPKalpha1 pathway activation by caulerpin in colorectal cancer cells. Int J Oncol (2017) 50:161-72. doi:10.3892/ijo.2016.3794
309. Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D, et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med (2011) 208:1949-62. doi:10.1084/jem.20101956
310. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med (2005) 11:312-9. doi:10.1038/nm1196
311. Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood (2010) 115:3520-30. doi:10.1182/blood-2009-09-246124
312. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 17:1094-100. doi:10.1038/nm.2438
313. Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood (2004) 104:1094-9. doi:10.1182/blood-2003-12-4266
314. Nika K, Soldani C, Salek M, Paster W, Gray A, Etzensperger R, et al. Constitutively active Lck kinase in T cells drives antigen receptor signal transduction. Immunity (2010) 32:766-77. doi:10.1016/j.immuni.2010.05.011
315. Luo J, Hong Y, Tao X, Wei X, Zhang L, Li Q. An indispensable role of CPT-1a to survive cancer cells during energy stress through rewiring cancer metabolism. Tumour Biol (2016) 37:15795-804. doi:10.1007/s13277-016-5382-6
316. Qian J, Chen Y, Meng T, Ma L, Meng L, Wang X, et al. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer. Oncotarget (2016) 7(41):67071-86. doi:10.18632/oncotarget.11490
317. Zeng H, Yang K, Cloer C, Neale G, Vogel P, Chi H. mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature (2013) 499:485-90. doi:10.1038/nature12297
318. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell (1994) 79:1147-56. doi:10.1016/0092-8674(94)90006-X
319. Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A (1999) 96:3951-6. doi:10.1073/pnas.96.7.3951
320. Tebbe C, Chhina J, Dar SA, Sarigiannis K, Giri S, Munkarah AR, et al. Metformin limits the adipocyte tumor-promoting effect on ovarian cancer. Oncotarget (2014) 5:4746-64. doi:10.18632/oncotarget.2012
321. Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, Chiavarina B, Pavlides S, Wang C, et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: a new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle (2010) 9:3256-76. doi:10.4161/cc.9.16.12553
322. Ibrahim-Hashim A, Wojtkowiak JW, de Lourdes Coelho Ribeiro M, Estrella V, Bailey KM, Cornnell HH, et al. Free base lysine increases survival and reduces metastasis in prostate cancer model. J Cancer Sci Ther (2011). doi:10.4172/1948-5956.S1-004
323. Ibrahim Hashim A, Cornnell HH, Coelho Ribeiro Mde L, Abrahams D, Cunningham J, Lloyd M, et al. Reduction of metastasis using a non-volatile buffer. Clin Exp Metastasis (2011) 28:841-9. doi:10.1007/s10585-011-9415-7
324. Ibrahim-Hashim A, Cornnell HH, Abrahams D, Lloyd M, Bui M, Gillies RJ, et al. Systemic buffers inhibit carcinogenesis in TRAMP mice. J Urol (2012) 188:624-31. doi:10.1016/j.juro.2012.03.113
325. Reichert M, Steinbach JP, Supra P, Weller M. Modulation of growth and radiochemosensitivity of human malignant glioma cells by acidosis. Cancer (2002) 95:1113-9. doi:10.1002/cncr.10767
326. Gerweck LE, Vijayappa S, Kozin S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol Cancer Ther (2006) 5:1275-9. doi:10.1158/1535-7163.MCT-06-0024
327. Morimura T, Fujita K, Akita M, Nagashima M, Satomi A. The proton pump inhibitor inhibits cell growth and induces apoptosis in human hepatoblastoma. Pediatr Surg Int (2008) 24:1087-94. doi:10.1007/s00383-008-2229-2
328. von Schwarzenberg K, Wiedmann RM, Oak P, Schulz S, Zischka H, Wanner G, et al. Mode of cell death induction by pharmacological vacuolar H+-ATPase (V-ATPase) inhibition. J Biol Chem (2013) 288:1385-96. doi:10.1074/jbc.M112.412007
329. Kastelein F, Spaander MC, Steyerberg EW, Biermann K, Valkhoff VE, Kuipers EJ, et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. Clin Gastroenterol Hepatol (2013) 11:382-8. doi:10.1016/j.cgh.2012.11.014
330. Ihnatko R, Kubes M, Takacova M, Sedlakova O, Sedlak J, Pastorek J, et al. Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia. Int J Oncol (2006) 29:1025-33. doi:10.3892/ijo.29.4.1025
331. Supuran CT. Development of small molecule carbonic anhydrase IX inhibitors. BJU Int (2008) 101(Suppl 4):39-40. doi:10.1111/j.1464-410X.2008.07648.x
332. Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res (2011) 71:3364-76. doi:10.1158/0008-5472.CAN-10-4261
333. Justus CR, Dong L, Yang LV. Acidic tumor microenvironment and pH-sensing G protein-coupled receptors. Front Physiol (2013) 4:354. doi:10.3389/fphys.2013.00354
334. Yang L, Achreja A, Yeung TL, Mangala LS, Jiang D, Han C, et al. Targeting stromal glutamine synthetase in tumors disrupts tumor microenvironment-regulated cancer cell growth. Cell Metab (2016) 24:685-700. doi:10.1016/j.cmet.2016.10.011
335. Singh S, Pandey S, Bhatt AN, Chaudhary R, Bhuria V, Kalra N, et al. Chronic dietary administration of the glycolytic inhibitor 2-Deoxy-D-Glucose (2-DG) inhibits the growth of implanted Ehrlich's ascites tumor in mice. PLoS One (2015) 10:e0132089. doi:10.1371/journal.pone.0132089
336. Newton R, Priyadharshini B, Turka LA. Immunometabolism of regulatory T cells. Nat Immunol (2016) 17:618-25. doi:10.1038/ni.3466
337. Kelly B, O'Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res (2015) 25:771-84. doi:10.1038/cr.2015.68
338. Pandey S, Singh S, Anang V, Bhatt AN, Natarajan K, Dwarakanath BS. Pattern recognition receptors in cancer progression and metastasis. Cancer Growth Metastasis (2015) 8:25-34. doi:10.4137/CGM.S24314